[1] McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. CIRCULATION. 2017; 135:e927-99.
[2] Lee HY, Song MS. Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease. Korean J Pediatr. 2016; 59:477-82.
[3] Ou-Yang MC, Kuo HC, Lin IC, Sheen JM, Huang FC, Chen CC, et al. Plasma clusterin concentrations may predict resistance to intravenous immunoglobulin in patients with Kawasaki disease. ScientificWorldJournal. 2013; 2013:382523.
[4] Baek JY, Song MS. Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Korean J Pediatr. 2016; 59:80-90.
[5] Ogata S, Ogihara Y, Nomoto K, Akiyama K, Nakahata Y, Sato K, et al. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. PEDIATR RES. 2009; 66:577-84.
[6] Kuo H, Wong HS, Chang W, Chen B, Wu M, Yang KD, et al. Prediction for Intravenous Immunoglobulin Resistance by Using Weighted Genetic Risk Score Identified From Genome-Wide Association Study in Kawasaki DiseaseCLINICAL PERSPECTIVE. Circulation: Cardiovascular Genetics. 2017; 10:e1625.
[7] Agarwal S, Agrawal DK. Kawasaki disease: etiopathogenesis and novel treatment strategies. EXPERT REV CLIN IMMU. 2017; 13:247-58.
[8] Shin J, Lee H, Eun L. Verification of Current Risk Scores for Kawasaki Disease in Korean Children. J KOREAN MED SCI. 2017; 32:1991.
[9] Qi Y, Gong F, Zhang Q, Xie C, Wang W, Fu S. Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease. ARTHRITIS RES THER. 2012; 14:R251.
[10] Yan L, Bjork P, Butuc R, Gawdzik J, Earley J, Kim G, et al. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. ATHEROSCLEROSIS. 2013; 228:69-79.
[11] Galeotti C, Kaveri SV, Bayry J. Molecular and immunological biomarkers to predict IVIg response. TRENDS MOL MED. 2015; 21:145-7.
[12] Maddur MS, Sharma M, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. J CLIN IMMUNOL. 2013; 33 Suppl 1:S62-6.
[13] Guo MM, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. ALLERGY. 2015; 70:310-8.
[14] Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clinical & Experimental Immunology. 2010; 162:131-7.
[15] Clark DE, Denby KJ, Kaufman LM, Fill MA, Piya B, Krishnaswami S, et al. Predictors of Intravenous Immunoglobulin Non-Response and Racial Disparities in Kawasaki Disease. The Pediatric Infectious Disease Journal. 2018:1.
[16] Inamo Y, Saito K, Hasegawa M, Hayashi R, Nakamura T, Abe O, et al. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study. BMC PEDIATR. 2014; 14:27.
[17] Takeuchi M, Inuzuka R, Hayashi T, Shindo T, Hirata Y, Shimizu N, et al. Novel Risk Assessment Tool for Immunoglobulin Resistance in Kawasaki Disease: Application Using a Random Forest Classifier. PEDIATR INFECT DIS J. 2017; 36:821-6.
[18] Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. EUR J PEDIATR. 2007; 166:131-7.
[19] Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006; 149:237-40.
[20] Kim MK, Song MS, Kim GB. Factors Predicting Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Lesion in Patients with Kawasaki Disease: Analysis of the Korean Nationwide Multicenter Survey from 2012 to 2014. KOREAN CIRC J. 2018; 48:71.
[21] Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008; 153:117-21.
[22] Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to Intravenous Immunoglobulin in Children with Kawasaki Disease. The Journal of Pediatrics. 2008; 153:117-21.
[23] Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. LANCET. 2014; 383:1731-8.
[24] Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. NAT REV RHEUMATOL. 2015; 11:475-82.
[25] Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol. 2015; 11:819-25.
[26] Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease. The Journal of Pediatrics. 2008; 153:833-8.
[27] Ding Y, Liu P, Chen Z, Zhang S, Wang Y, Cai X, et al. Emodin Attenuates Lipopolysaccharide-Induced Acute Liver Injury via Inhibiting the TLR4 Signaling Pathway in vitro and in vivo. FRONT PHARMACOL. 2018; 9.
[28] Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. ACTA PAEDIATR. 2010; 99:1578-83.
[29] Wakiguchi H, Hasegawa S, Suzuki Y, Kudo K, Ichiyama T. Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease. PEDIATR RES. 2015; 77:536-40.
[30] Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J IMMUNOL. 2005; 174:5837-45.
[31] Nomura Y, Masuda K, Yoshinaga M, Sameshima K, Miyata K. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm. PEDIATR INT. 2002; 44:353-7.
[32] Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. Singapore Med J. 2006; 47:780-4.
[33] Wang Y, Li Z, Hu G, Hao S, Deng X, Huang M, et al. Unique Molecular Patterns Uncovered in Kawasaki Disease Patients with Elevated Serum Gamma Glutamyl Transferase Levels: Implications for Intravenous Immunoglobulin Responsiveness. PLOS ONE. 2016; 11:e167434.
[34] Sileikiene R, Kudzyte J, Jankauskas A, Labanauskas L, Rakauskiene V, Jurkiene N, et al. Rare refractory Kawasaki disease in an adolescent boy with cardiac and diffuse coronary artery involvement. Medicina (Kaunas). 2013; 49:341-5.
[35] Lee HY, Song MS. Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease. Korean Journal of Pediatrics. 2016; 59:477.
[36] Fu S, Gong F, Xie C, Zhu W, Wang W, Shen H, et al. S100A12 on circulating endothelial cells surface in children with Kawasaki disease. PEDIATR RES. 2010; 68:165-8.
[37] Fury W, Tremoulet AH, Watson VE, Best BM, Shimizu C, Hamilton J, et al. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. HUM IMMUNOL. 2010; 71:865-73.
[38] Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. LANCET. 2003; 361:1270-2.
[39] Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. CLIN EXP IMMUNOL. 2010; 162:131-7.
[40] Lok KZ, Basta M, Manzanero S, Arumugam TV. Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia. J Neuroinflammation. 2015; 12:73.
[41] Wu S, Zhang X, Zhou N. [Up-regulation of serum- and glucocorticoid-inducible kinase 1 (SGK1) of CD4(+) T cells is positively related to RORC and IL-17A in patients with Kawasaki disease]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015; 31:1378-82.